髓源性抑制细胞在脓毒症中的研究进展  

Research progress of myeloid derived suppressor cells in sepsis

作　　者：刘娟丽[1,2] 马四清 乌仁塔娜[2] Liu Juanli;Ma Siqing;Wurentana(Department of Critical Care Medicine,Qinghai Provincial People's Hospital,Xining 810007,China;Plateau Medical Center of Qinghai University,Xining 810001,China)

机构地区：[1]青海省人民医院重症医学科,西宁810007 [2]青海大学高原医学研究中心,西宁810001

出　　处：《中华重症医学电子杂志》2024年第3期271-278,共8页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

基　　金：青海省高原医学应用基础重点实验室(青海-犹他高原医学联合重点实验室)项目(2022-ZJ-Y15);青海省卫生健康委员会指导性课题(2020-wjzdx-01);青海省高原重症医学重点实验室项目(2020-81)

摘　　要：脓毒症是收住ICU的主要原因,从脓毒症定义来看,脓毒症始发于感染,发展于机体的免疫反应失调,恶化在组织和器官。脓毒症的发病机制复杂,多种机制参与其病理生理过程,机体的免疫状态严重失衡。随着ICU医师对脓毒症的不断认识及医疗技术的快速提升,脓毒症患者一般能度过早期的炎症风暴,而后期因免疫抑制导致二次感染,从而增加了病死率。目前针对脓毒症的研究主要集中在免疫抑制及寻找免疫调节治疗两个方面。本文就近年来髓源性抑制细胞(MDSC)的命名、来源以及在脓毒症免疫中的研究进展进行综述,为脓毒症免疫失调寻找潜在的治疗方法提供重要的理论基础。Sepsis is the main cause of ICU admission.Sepsis originates from an infection and progresses due to host desregulated immune response,ultimately leading to deterioration in tissues and organs.The pathogenesis of sepsis is complicate,with multiple mechanisms involved in its pathological and physiological processes.The immune state of the body is significantly disrupted.Thanks to the ongoing advancements in medical technology and the increasing knowledge of sepsis by ICU physicians,sepsis patients can typically endure the initial inflammatory response.However,in the later stages,they are susceptible to secondary infections due to immune suppression,which still carries a significant risk of mortality.At present,the research on sepsis mainly focuses on immunosuppression and immunomodulatory strategies.We review the nomenclature,origin,and research progress of myeloid suppressor cells(MDSCs)in sepsis in this manuscript.It also presents the theoretical foundation for future treatments of sepsis-related immune dysfunctions.

关 键 词：脓毒症 髓源性抑制细胞 分化 高原地区 

分 类 号：R459.7[医药卫生—急诊医学]